ArticleVirus research2026
Identification of key genes modules linking brain aging signatures and COVID-19-associated cognitive impairment.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Folic Acid and Endothelial Dysfunction in COVID-19.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence indicates that SARS-CoV-2 infection is associated with aging, particularly in memory-related domains. However, the molecular mechanisms underlying COVID-19-associated aging, often referred to as "brain fog," remain poorly understood. This study aimed to identify key genes implicated in post-COVID cognitive dysfunction.
methodsTranscriptomic data from the frontal cortex, obtained from the GEO dataset GSE188847 and GSE164332, were analyzed using differential expression analysis to identify differentially expressed genes (DEGs) associated with brain fog. Functional enrichment analysis was conducted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Machine learning techniques, including LASSO regression and weighted gene co-expression network analysis (WGCNA), were employed to identify hub genes. Drug-gene interactions were explored using the Comparative Toxicogenomics Database (CTD).
resultsA total of 81 up-regulated and 441 down-regulated DEGs were identified in COVID-19 patients compared to controls. Up-regulated genes were primarily enriched in pathways related to pulmonary fibrosis and immune activation (e.g., IL-17 signaling), while down-regulated genes were associated with synaptic transmission (e.g., GABAergic synapse, adjusted p = 0.003). Integration of LASSO and WGCNA analyses revealed five aging-related hub genes: SST, S100A9, SOCS3, FKBP5, and HBB. Notably, SST expression was significantly reduced, whereas the other four genes showed marked upregulation. CTD analysis identified seven potential therapeutic agents: fulvestrant, bucladesine, S-adenosylmethionine, valproic acid, folic acid, kaempferol, and quercetin.
conclusionsThis study employed transcriptomic analysis and bioinformatics approaches to identify five key aging-related genes associated with COVID-19. These genes may serve as potential therapeutic targets for addressing COVID-19-associated aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.